Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

Published:2013-09-05 Issue:7 Volume:109 Page:1755-1759
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Santoni M,De Giorgi U,Iacovelli R,Conti A,Burattini L,Rossi L,Luca Burgio S,Berardi R,Muzzonigro G,Cortesi E,Amadori D,Cascinu S

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2013522.pdf

Reference35 articles.

1. Alexandrescu DT, Dasanu CA (2006) Kidney cancer therapy: new perspectives and avenues. Expert Opin Pharmacother 7: 2481–2493.

2. An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH, Jiang WQ (2010) Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 15: 516–522.

3. Beyrau M, Bodkin JV, Nourshargh S (2012) Neutrophil heterogeneity in health and disease: a revitalized avenue in inflammation and immunity. Open Biol 2: 120134.

4. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58: 15–23.

5. de Martino M, Klatte T, Seemann C, Waldert M, Haitel A, Schatzl G, Remzi M, Weibl P (2013) Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC). BJU Int 111: E348–E353.

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study;Cancer Immunology, Immunotherapy;2024-07-02

2. Relationship of the Neutrophil–Lymphocyte Ratio with All-Cause and Cardiovascular Mortality in Patients with Diabetic Kidney Disease: A Prospective Cohort Study of NHANES Study;Journal of Multidisciplinary Healthcare;2024-05

3. Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey;Annals of Hematology;2024-04-17

4. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of Meet-URO15 study;2024-02-28

5. NLCECA score: a serum inflammatory-tumor biomarker score to predict survival of advanced perihilar cholangiocarcinoma after hepatic arterial infusion chemotherapy;Scientific Reports;2024-02-23